Compare CDMOs with immunology drug manufacturing expertise for monoclonal antibodies, bispecifics, cell therapies, and immunomodulators. Filter by modality, scale, and regulatory approvals.
133 companies listed
Immunology manufacturing is at the intersection of the largest biologic drug classes. Monoclonal antibodies targeting immune pathways (anti-TNF, anti-IL-6, anti-PD-1/PD-L1) account for the majority of biologic drug revenue globally. The field continues to expand with bispecific antibodies, ADCs, CAR-T cell therapies, and next-generation immunomodulators that require increasingly specialized manufacturing capabilities.
Bispecific antibodies are the next manufacturing challenge. Unlike standard monoclonal antibodies, bispecifics (targeting two different antigens simultaneously) require novel production strategies: knobs-into-holes, CrossMab, common light chain, or tandem scFv formats. Each format has different upstream and downstream manufacturing requirements. CDMOs with experience across multiple bispecific platforms provide strategic flexibility for sponsors developing these next-generation immunotherapies.
Cell therapy manufacturing for immunological applications extends beyond oncology. CAR-T and TCR-T therapies are being developed for autoimmune diseases (lupus, multiple sclerosis), transplant rejection, and chronic infections. Manufacturing requirements are similar to oncology cell therapies -- GMP-grade viral vectors, cell processing in classified environments, cryopreservation, and patient-specific supply chain logistics -- but the scale and disease-specific modifications may differ.
Malaysia
Symbiotica Speciality Ingredients is a Malaysian-based manufacturer of steroidal, hormonal, and niche non-steroidal Active Pharmaceutical Ingredients. With over 20 years of experience, the company serves 250+ customers across 80+ countries with 78+ API products. The company holds PIC/s cGMP certification and products comply with US FDA, CEP, PMDA, and other global standards. Symbiotica also offers custom API manufacturing solutions from development to commercial production.
China
Taizhou Dachen Pharmaceutical is a Chinese API and pharmaceutical intermediates manufacturer established in 2017, located in the Zhejiang Chemical API Base (Linhai Park). It is a subsidiary of the Richu Industrial Group. The company specializes in R&D, production, and sales of pharmaceutical raw materials, intermediates, and specialty chemicals. Key products include diacerein, aloe-emodin, rhein, minocycline HCl, tigecycline, and duloxetine HCl. They supply to Bayer, Merck, and other international pharma companies. FDA-registered for API manufacture with 2 inspections (1 NAI, 1 VAI). ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 certified. National high-tech enterprise designation.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.